d Swedish Cancer Institute

Seattle, WA, United States

d Swedish Cancer Institute

Seattle, WA, United States
SEARCH FILTERS
Time filter
Source Type

PubMed | f Banner Anderson Cancer Center, Arizona Cancer Center, d Swedish Cancer Institute, University of Arizona and Mayo Medical School
Type: Clinical Trial, Phase I | Journal: Cancer investigation | Year: 2016

To establish the maximum tolerated dose (MTD) and safety profile of bi-weekly Pemetrexed (PEM) when combined with weekly cisplatin (CDDP) and standard dose external beam radiation (EBRT) in patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) carcinomas.We conducted an open label, single institution, phase I dose escalation study designed to evaluate up to 15-35 patients with advanced or metastatic esophageal and GEJ carcinomas.10 patients were treated with bi-weekly PEM, weekly CDDP, and EBRT. The MTD of bi-weekly PEM was determined to be 500 mg/m(2).

Loading d Swedish Cancer Institute collaborators
Loading d Swedish Cancer Institute collaborators